Aurora B antibody is a critical tool in studying the Aurora B kinase, a serine/threonine-protein kinase central to mitosis and cell division. Aurora B, part of the chromosomal passenger complex (CPC), regulates key mitotic events such as chromosome alignment, spindle assembly, cytokinesis, and correction of microtubule-kinetochore attachment errors. Dysregulation of Aurora B is linked to genomic instability, aneuploidy, and cancer progression, making it a target for anticancer therapies.
Aurora B antibodies are widely used in research to detect and quantify Aurora B expression, localization, and activity in cells and tissues. They enable techniques like Western blotting, immunofluorescence, immunohistochemistry, and flow cytometry, aiding in the study of cell cycle dynamics, mitotic defects, and drug response. Specific antibodies may target distinct phosphorylation sites (e.g., Thr232. Ser331) or regions to assess activation states or interactions with binding partners.
These antibodies also have diagnostic applications, as Aurora B overexpression correlates with tumor aggressiveness and poor prognosis in cancers like breast, colorectal, and ovarian. Additionally, they are instrumental in validating Aurora B inhibitors in preclinical models. Researchers must select antibodies validated for species reactivity, post-translational modifications, and assay compatibility to ensure specificity and reproducibility. Commercial Aurora B antibodies are typically raised in hosts like rabbits or mice, with clones characterized for cross-reactivity and performance in diverse experimental systems.